Supernus Pharmaceuticals, Inc. (SUPN) key performance indicators and operating metrics (12 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Net Product Sales | 150.8M | FY2026-Q1 |
| GoCovri Net Product Sales | 35.2M | FY2026-Q1 |
| Net Product Sales of Qelbree | 77.9M | FY2026-Q1 |
| Total Qelbree IQVIA Prescriptions | 254.82K | FY2026-Q1 |
| Net Product Sales of Onapgo | 8.4M | FY2026-Q1 |
| Collaboration Revenue from ZurzuvAE | 27.6M | FY2026-Q1 |
| Combined Revenue of the Four Growth Products | 149.1M | FY2026-Q1 |
| Qelbree Prescribers | 43K | FY2026-Q1 |
| Licensing Revenue Related to Regulatory Milestone (Shionogi) | 20M | FY2026-Q1 |
| Adjusted Operating Earnings (Non-GAAP) | 48.5M | FY2025-Q4 |
| Onapgo Enrollment Forms Submitted Since Launch | 1.8K | FY2025-Q4 |
| Onapgo Prescribers Submitting Enrollment Forms | 540.00 | FY2025-Q4 |
Back to SUPN overview · SUPN earnings · SUPN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.